& TRADERAN

Sheet

Substitute for form 1449A/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Application Number	10/616,178			
Filing Date	July 8, 2003			
First Named Inventor	BROWN, Dennis M.			
Art Unit	1625			
Examiner Name	TRINH, Ba K.			
Attorney Docket Number	A-71462/RFT/THR (468899-00034)			

	U.S. PATENT DOCUMENTS				
Examiner tritials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
R	A1	4,204,063	05-20-1980	Brana et al.	
D	A2 *	5,206,249	04-27-1993	Sun	
D	A3 •	5,376,664	12-27-1994	Kaltenbach, III et al.	
as	A4 *	5,416,089	05-16-1995	Patten et al.	
P	A5	5,420,137	05-30-1995	Brana et al.	
P	A6 *	5,461,176	10-24-1995	Sun et al.	
Jo.	A7 *	5,585,382	12-17-1996	Patten et al.	
o	A8 *	6,177,423 B1	01-23-2001	Amegadzie et al.	
	A9 •	6,361,181 B1	03-26-2002	Amegadzie et al.	
121	A10	6,630,173 B2	10-07-2003	Brown	
W	A11	6,693,198 B2	02-17-2004	Ajami et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ¹ Number ⁴ Kind Code ⁵ (if known)	Publication Data MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	79
100	B1	DE 4 023 241	01-23-1992	Knoli AG		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city end/or country where published.	Τª		
RO	C1	BRAÑA, M.F., et al., "Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones," ArzneimForsch/Drug Res. 45(12):1311-1318 (Dec. 1995).			
R	C2	CAMACHO, M.A., et al., "Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets," ArzneimForsch/Drug Res. 44(5):659-662 (May 1994).			
B	C3	CAMACHO-SANCHEZ, M.A., et al., "Stability of amonafide solutions in front of light and temperature," Clenc. Ind. Farm. 8:104-109 (Mar. – Apr. 1989).			
R	C4	OBREGÓN, M.M., et al., "Compatibility study of amonafide-HC1 with hydrophobic excipients," Conf. Proc. 1 st World Mtg. Pharm. Biopharm. Pharm. Technol., Budapest, HU (May 9 – 11, 1995).			
Ro	C5	TORRES SUÁREZ, A.I., et al., "The behavior under atmospheric humidity of two benzoisoquinolinediones (mitonafide and amonafide dihydrochloride)," Farmaco 46(9):1091-1096 (Aug. 1991).			
lo	C6	TORRES, A.I., et al., "Design and formulation of tablets of a new antineoplastic drug: amonafide," <i>Drug Devel. Ind. Pharm.</i> 21(2):185-197 (1995).			

	20		
Examiner Signature	Wesar	Date Considered	10/17/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through ditation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

The Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.

It is possible.

Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.